170 results about "Acute leukemia" patented technology

Methods for assessing a pathological condition in a subject include measuring one or more markers where a difference is indicative of acute lymphoblastic leukemia (ALL) or a predisposition to ALL, uses and compositions are disclosed.

The invention discloses a preparation method of an electrochemical sensor capable of simultaneously detecting two acute leukemia markers. The method comprises the following steps: respectively standing a lysozyme report probe and a gamma-interferon report probe in a liquid containing trichloroethyl phosphate (TCEP), so as to open a disulfide bond and respectively form a double-chain structure together with a lysozyme aptamer and a gamma-interferon aptamer; preprocessing a gold electrode, and immersing the processed gold electrode into the pre-processed mixed liquid of lysozyme report probe-aptamer double chains and gamma-interferon report probe-aptamer double chains; standing at room temperature over the night, and then cleaning by using secondary distilled water and a cleanout fluid; immersing the electrode into the liquid containing MCH to seal the electrode, and then cleaning the secondary distilled water and the cleanout fluid; and taking the electrode processed by the above steps as a work electrode to be connected on a chemical work station together with a reference electrode and a counter electrode, so as to obtain the electrochemical sensor. The electrochemical sensor can be applied to simultaneous detection of two acute leukemia markers, namely lysozyme and gamma-interferon.

The invention discloses an automatic classification method for bone marrow cells. The method comprises the following steps: (1), carrying out saturation-based pre-detection of bone marrow cells; (2),carrying out bone marrow cell detection based on sparse representation; (3), carrying out morphology-based multi-angle bone marrow cell segmentation; (4), carrying out deep-learning-based bone marrowcell classification. According to the invention, an accurate bone marrow cell detection position, an accurate classification image, and an accurate classification result are obtained; no manual participation is needed during the whole process; the full-automatic bone marrow cell detection, segmentation and classification are realized truly; and follow-up medical treatment like acute leukemia diagnosis can be carried out conveniently.

Overexpression of the gene, BAALC, in biological samples from a patient is prognostic for tumor aggressiveness and unfavorable patient outcome. The present invention provides polynucleotide primers and probes for assaying for overexpression of BAALC transcripts. Kits containing the primers and probes are also provided. Also provided are antibodies for assaying for overexpression of BAALC proteins as well as peptide immunogens for producing the anti-BAALC antibodies. The present invention also provides methods for characterizing acute myelogenous leukemia, chronic myelogenous leukemia and prostate cancer in a patient, base on detection of BAALC overexpression.

An application of eriocalyxin B in preparing the medicines for treating acute leukemia and Burkitt's lymphoma is disclosed.

The invention relates to the field of pharmaceutical chemistry, in particular to medical use of 34 compounds and medicinal composition containing the compounds, particularly use as Polo like kinase 1 inhibitor. Diseases associated with the Polo like kinase 1 inhibitor include melanoma, liver cancer, kidney cancer, acute leukemia, non-small-cell lung cancer, prostatic cancer, cancerous goiter, skin cancer, colorectal cancer, pancreatic cancer, ovarian cancer, breast cancer, myelodysplastic syndromes, esophageal cancer, gastrointestinal tract cancers or mesothelioma.

The invention provides 2-arylamine pyrimidine derivatives containing hydroxamic acid fragments shown in the formulas I and II. 2-arylamine pyrimidine containing carboxyl fragments is mainly used as a parent nucleus and is subjected to single-step condensation and related modification with hydroxylamine protected by THP to obtain a target compound. An experiment proves that the derivatives has the remarkable anti-proliferative effect on tumor cells (an overexpression EGFR human epidermal carcinoma cell line A431 and a human pulmonary carcinoma cell line H1975 resisting Gefitinib) related to EGFR tyrosine kinase activity on the cellular level, and tumor cells (a human cervical carcinoma cell line Hela, a human hepatoma cell line HepG2, a human promyelocytic acute leukemia cell line HL60, a human oral epidermoid carcinoma cell line KB, a human colon cancer cell line SW620) related to the HDAC histone acetylase activity, and the corresponding medicine for resisting cancer cells can be prepared. The general structural formula is shown in the description.

The present invention discloses a bone marrow cell segmentation method based on sparse representation and morphological operation. The method comprises the following steps of: (1) pre-detection of bone marrow cells based on saturability; (2) detection of the bone marrow cells based on sparse representation; and (3) segmentation and counting of multi-angle bone marrow cells based on the morphology.The bone marrow cell segmentation method based on sparse representation and morphological operation can obtain an accurate bone marrow cell detection position, a segmentation image and a counting result, the whole process does not need human intervention, the automatic bone marrow cell detection, segmentation and counting can be really achieved to facilitate subsequent treatment such as cell classification and acute leukemia diagnosis.

Methods of treatment and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia, and myelodysplastic syndrome. The methods of treatment and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog. Preferred methods of treatment and pharmaceutical combinations employ gemtuzumab ozogamicin, daunorubicin, and cytarabine.

The invention discloses a fluorescent probe and a kit for carrying out differential diagnosis on leukemia and bone marrow metastasis of rhabdomyosarcoma and neuroblastoma by using flow cytometry. The fluorescent probe comprises four fluorescence labeled antibodies; the four fluorescence labeled antibodies comprise a GD2 antibody, a CD90 antibody, a CD45 antibody and a CD56 antibody which take fluorescence labels; the different antibodies take the different fluorescence labels. The kit comprises a probe solution, a hemolytic agent, a phosphate buffer and a positive standard product. The fluorescent probe can be respectively and specifically combined with cells of the rhabdomyosarcoma and the neuroblastoma in bone marrow and original cells of acute leukemia; three tumor cells which are common in the child bone marrow, such as the bone marrow metastasis of the rhabdomyosarcoma and the neuroblastoma and the leukemia cells, can be rapidly and accurately identified by the flow cytometry, so as to guide clinical treatment; the application prospect is very good.

The invention discloses a preparation method of superparamagnetism conductive nano gamma-ferric oxide / polyaniline-dexamethasone sodium phosphate, relating to the technical field of synthesis of superparamagnetism conductive nano gamma-ferric oxide / polyaniline-dexamethasone sodium phosphate. The superparamagnetism conductive nano gamma-ferric oxide / polyaniline-dexamethasone sodium phosphate is prepared by a doping method. The product of the invention can better suspend in water, still has favorable electrochemical activity and electric conduction magnetoconductivity within the pH range of human body environment, and can directionally reach diseased tissues under the regulation and control of an external magnetic field without damaging normal clasmatocyte. The targeted medicine is hopefully applied to treating acute leukemia, malignant lymphoma, connective tissue diseases, rheumatoid arthritis and the like. In addition, the method of the invention is simple, convenient, economical and favourable for industrial production and application.

The invention discloses an artemisinin detrivative and an application of its medicinal salt. The artemisinin detrivative di-arteether-yl-amine and its medicinal salt can inhibit the proliferation of leukemic cells, arrest the tumor cell cycle, and induce the apoptosis of tumor cells. The artemisinin detrivative di-arteether-yl-amine and its medicinal salt can be used in preparing medicines for treating leukemia, especially in medicines for treating acute leukemia, and more particularly in medicines for treating acute myeloid leukemia.

The invention relates to a novel stable protein kinase activator adenosine cyclophosphate salt derivate, which has high storage stability and preparation performance and can be used in the preparation of medicaments for treating or preventing the following human and animal diseases such as stenocardia, cardiac failure, myocardial infarction, myocarditis, arrhythmia, cardiogenicshock, acute leukemia, nerve system diseases, respiratory system diseases, senile chronic bronchitis, hepatitis, psoriasis and the like and relieving the symptoms, such as cardiopalmus, shortness of breath, chest distress and the like of rheumatic heart disease.

The present invention relates to a novel N-phenyl-2-pyrimidine-amine derivative represented by the above formula (1) and its salt showing a superior effect on cancer in warm-blooded animals, such as lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, cervical cancer, lymphoma, etc. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.

The invention provides a reagent composition for screening and / or diagnosing clonal diseases by a one-step method and application of the reagent composition. The reagent composition comprises eight groups of antibodies and is a flow cytometry detection composition capable of being used for one-step screening and / or diagnosis of clonal diseases, a five-tube parallel scheme is used during application, the first group of antibodies and the second group of antibodies are respectively used for different tube samples, the third group of antibodies and the sixth group of antibodies are used for the same tube sample, the fourth group of antibodies and the seventh group of antibodies are used for the same tube sample, and the fifth group of antibodies and the eighth group of antibodies are used for the same tube sample. The reagent composition disclosed by the invention can be applied to flow cytometry one-step screening / diagnosis of various clonal diseases and other abnormalities, comprising acute leukemia, mature lymphocyte tumor, chronic myeloid tumor, night paroxysmal sleep hemoglobinuria, metastatic cancer, precancerous lesions, rare normal human polymorphisms, aplastic anemia, other immune cell subset abnormalities and the like.

The present invention relates to a novel N-phenyl-2-pyrimidine-amine derivative represented by the above formula (1) and its salt showing a superior effect on cancer in warm-blooded animals, such as lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, cervical cancer, lymphoma, etc. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.

A method of treating leukemia by administering an H4 agonist of histamine, 7-amino-4,5,6-triethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl) phthalide (tritoqualine), to a subject is provided.

The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.

Provided is a detection method of an electrochemical acute leukemia gene Pax-5a based on enzyme assisted cyclic signal amplification; the efficiency advantage of transcription termination and translation is controlled based on a hairpin DNA probe (HP). The target gene Pax-5a opens HP, and the replication template function of the HP is started. Under the synergistic effect of DNA polymerase and restriction endonuclease, on one hand, auxiliary DNA promotes the target gene Pax-5a to cyclically open the HP; on the other end, a large number of G-quadruplex sequences are produced. The G-quadruplex sequences are captured by a sulfhydryl-modified probe on the surface of a gold electrode due to the complementary action of bases, then a G-quadruplex / hemin complex is formed in the presence of hematinchloride and potassium ions, and hydrogen peroxide can be catalyzed to reduce so as to generate electrochemical signals; the change of the current has linear correlation relationship with the concentration of the target gene in a certain range. Based on the mechanism of enzyme assisted cyclic signal amplification of the hairpin DNA probe and a one-key electrochemical detection platform, high-sensitivity and high-selectivity detection of the target gene can be achieved.

The present invention relates to a novel N-phenyl-2-pyrimidine-amine derivative represented by the above formula (1) and its salt showing a superior effect on cancer in warm-blooded animals, such as lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, cervical cancer, lymphoma, etc. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.

The present invention relates to the application of the metabolite Tagalsin C of marine life and its homologs Tagalsins A, B, D, E, F and G in preparing medicine for treating tumor. The series of compounds has high membrane permeability and broad spectrum antitumor activity of killing human promyelocytic acute leukemia cell HL-60, human myeloma cell IM9, human acute T-cell leukemia cell Jurkat, human macrophage lymphoma cell U937, human lung cancer cell A549, etc, and no obvious injury on health human nephridium cell 293aa human liver diploid cell L02. The series of compounds may be used in preparing medicine for treating tumor, medicine with high clinical Bcl-2 expression and conventional chemotherapy resistance, and medicine for treating cancer recurrence.

The invention discloses a medicament for treating acute leukemia and a preparation method thereof. The medicament is mainly prepared from rhizoma anemarrhenae, pinellia ternate, dried rehmannia root, licorice, sophora flavescens, herba agrimoniae and other drugs according to certain weight ratios. The medicament has functions of removing pathogenic heat from blood, tonifying the kidney, nourishing yin and promoting secretion, and is used for treating acute leukemia.

The invention discloses emodin as an inhibitor of activated molecules p-Akt and p-mTOR of a PI3K / Akt / mTOR signal transduction pathway and application thereof, wherein the emodin is a purely natural anthraquinone monomer compound extracted from rhubarb as a Chinese traditional medicine and has multiple biologic activities such as anti-microbes, anti-inflammation, antioxidation, immune regulation, liver protection and the like. The invention finds that after acute leukemia multidrug-resistance cells HL-60 / ADR, acute promyelocytic leukemia retinoic acid drug-resistant cells MR2 as well as corresponding sensitive cells NB4 and acute leukemia primary cells are acted by the rhubarb, key signal activated molecules of the PI3K / Akt / mTOR signal transduction pathway, particularly p-Akt and p-mTOR, are inhabited with specificity; in vivo researches verify that after the emodin is dosed, all the key activated molecules p-Akt, p-p65 and p-mTOR of the PI3K / Akt / mTOR signal pathway in acute leukemia nude mouse transplanted tumor tissue protein are expressed and downwards regulated, which indicates that the emodin can be used as a novel targeting inhibitor for PI3K / Akt / mTOR signal transduction activated molecules, particularly p-Akt and p-mTOR, and is applied to treating malignant tumors of a blood system.

The invention discloses application of a snake venom-sourced cytotoxin-CTX1 to preparation of an acute leukemia resisting medicine. Experiments prove that the snake venom-sourced cytotoxin-CTX1 can inhibit the proliferation of a leukemia cell, can induce non-viable apoptosis and necrosis of HL-60 cell and KG1a cell, and has obvious medicinal effect in the aspect of leukemia resistance; therefore, the snake venom-sourced cytotoxin-CTX1 can be further developed into anti-tumor medicines with high efficiency, low toxicity and low drug tolerance.

Methods for assessing a pathological condition in a subject include measuring one or more markers where a difference is indicative of acute lymphoblastic leukemia (ALL) or a predisposition to ALL, uses and compositions are disclosed.

The invention discloses application of reversible crosslinked asymmetric vesicles in preparation of medicines for treating acute leukemia. An improved nano-vesicle carrier is used for loading proteinacting in cells, so that the targeted delivery of tumor cells in a whole body is realized, the medicines are rapidly released in the tumor cells, and the aim of treating the tumors with high efficiency and low toxicity is further achieved. The result prove that HA-RCP-GrB has high anti-tumor efficiency and low toxic and side effects in a human acute myeloid leukemia AML-2 subcutaneous tumor model,so that the survival time of a model mouse is significantly improved.

The invention provides application of a rhinoceros horn and rehmannia glutinosa composition in preparation of a medicine for preventing and treating related rash caused by an epidermal growth factor receptor inhibitor. The rhinoceros horn and rehmannia glutinosa composition includes rhinoceros horns, radix paeoniae rubra, radix rehmanniae and cortex moutan serving as effective ingredients. The medicine composition prepared by rhinoceros horn and rehmannia glutinosa decoction for treating severe hepatitis, hepatic coma, uremia, allergic purpura, acute leukemia, sepsis syndrome and other symptoms is creatively used for preventing and treating the rash caused by the epidermal growth factor receptor inhibitor, is better in clinical curative effect and low in toxicity and can be taken for a long time.

Methods of treatment and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia, and myelodysplastic syndrome. The methods of treatment and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog. Preferred methods of treatment and pharmaceutical combinations employ gemtuzumab ozogamicin, daunorubicin, and cytarabine.

A radioactive protection micronutrient formulation system is provided and the system comprises: a formulation consisting essentially of antioxidants, the antioxidants are selected from the group consisting essentially of vitamin C, vitamin E, N-acetyl cysteine, natural mixed carotenoids, and alpha-lipoic acid, vitamin A (palmitate), vitamin D-3 (cholecalciferol), thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid, D-Biotin, selenium (1-seleno-methionine), chromium picolinate, zinc glycinate, calcium citrate and magnesium citrate and mixtures thereof; and plus a booster formulation selected from a group consisting essentially of vitamin C, d-alpha tocopheryl acid succinate, alpha tocopherol, N-acetyl cysteine, natural mixed carotenoids and alpha lipoic acid, the formulation is designed to reduce the risk in humans exposed to doses of ionizing radiation of becoming subjected to at least one condition selected from the group consisting essentially of radiation-induced acute leukemia, breast cancer, thyroid cancer and other somatic and heritable mutations.